Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LutrePulse Hypogonadotropic Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01976728
Recruitment Status : Completed
First Posted : November 6, 2013
Results First Posted : March 3, 2021
Last Update Posted : March 3, 2021
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals

Brief Summary:
To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the OmniPod pump versus placebo

Condition or disease Intervention/treatment Phase
Primary Amenorrhea With Hypogonadotropic Hypogonadism Drug: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump Drug: Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump Drug: Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump Drug: Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism
Actual Study Start Date : April 1, 2014
Actual Primary Completion Date : February 23, 2018
Actual Study Completion Date : February 23, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LutrePulse 10 µg/pulse
Gonadorelin acetate 10 µg/pulse
Drug: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump
Other Name: LutrePulse

Experimental: LutrePulse 15 µg/pulse
Gonadorelin acetate 15 µg/pulse
Drug: Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump
Other Name: LutrePulse

Experimental: LutrePulse 20 µg/pulse
Gonadorelin acetate 20 µg/pulse
Drug: Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump
Other Name: LutrePulse

Placebo Comparator: Placebo
Placebo
Drug: Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)



Primary Outcome Measures :
  1. Ovulation Rate [ Time Frame: From treatment Day 1 up to 4 weeks after second positive β-hCG test, approximately 9 weeks ]
    Calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL or subjects with confirmed positive serum β-human chorionic gonadotropin (β-hCG) (i.e., 2 positive results) or subjects with a gestational sac documented by transvaginal ultrasound (TVUS).


Secondary Outcome Measures :
  1. Progesterone (P4) Levels [ Time Frame: Treatment Days 19, 21, 23, 25, and 27 ]
    Proportion of participants with at least 1 post-baseline P4 level ≥ 10 ng/mL.

  2. Clinical Pregnancy Rate [ Time Frame: 2 to 4 weeks after a second positive serum β-hCG test ]
    Proportion of subjects with presence of gestational sac and fetal heart movement on TVUS after a second positive serum β-hCG test.

  3. Biochemical Pregnancy Rate [ Time Frame: Approximately 14 days after LH surge ]
    Proportion of subjects with a confirmed positive serum β-hCG test after luteinizing hormone (LH) surge.

  4. LH Surge Detection [ Time Frame: Daily from Day 11 until first positive LH surge or until Day 39 ]
    Proportion of subjects with a positive detection of LH surge, based on a Clearblue test which began when follicles with a mean diameter ≥14 mm were documented on TVUS.

  5. Ovarian Follicular Development: Number of Follicles With a Mean Diameter Greater Than or Equal to (≥)14 mm [ Time Frame: From treatment Day 10 to treatment Day 21 ]
    Number of follicles with a mean diameter ≥14 mm collected from Days 10 or 11, until LH surge or Day 21.

  6. Ovarian Follicular Development: Number of Dominant Follicles With a Mean Diameter of ≥18 mm [ Time Frame: From treatment Day 10 to treatment Day 21 ]
    Number of dominant follicles with a mean diameter ≥18 mm collected from Days 10 or 11, until LH surge or Day 21.

  7. Luteal Phase Support: Maximum P4 Levels [ Time Frame: Treatment Days 19, 21, 23, 25, and 27 ]
    Maximum of post-dose P4 levels collected on treatment Days 19 to 27 are presented.

  8. Luteal Phase Support: Mean P4 Levels [ Time Frame: Median post-dose P4 values across Treatment Days 19, 21, 23, 25, and 27 ]
    Mean of post-dose P4 levels collected on treatment Days 19 to 27 are presented.

  9. Change From Baseline in Follicle-stimulating Hormone (FSH) [ Time Frame: Baseline (pre-dose), Treatment Day 1, Treatment Day 10 ]
    FSH change from baseline in relation to the first dose (pulse) on Day 1 and Day 10

  10. Change From Baseline in LH [ Time Frame: Baseline (pre-dose), Treatment Day 1, Treatment Day 10 ]
    LH change from baseline in relation to first dose (pulse) on Day 1 and Day 10

  11. Mean Serum FSH and LH Levels [ Time Frame: Treatment Days 1 and Day 10 ]
    Mean FSH and LH levels on Day 1 and Day 10.

  12. Estradiol (E2) Serum Levels [ Time Frame: At treatment Day 1 and Day 10 ]
    E2 serum levels on Day 1 and Day 10.

  13. Type, Intensity, and Frequency of Adverse Events (AEs) [ Time Frame: From treatment Day 1 to end-of-trial, approximately 10 weeks ]
    An AE was defined as any untoward medical occurrence in a subject taking part in a clinical trial. Proportion of subjects with any AE (serious or non-serious) and intensity of AEs (classified as mild, moderate or severe) are presented.

  14. Hematology, Clinical Chemistry, and Urinalysis [ Time Frame: From treatment Day 1 to end-of-trial, approximately 10 weeks ]
    Proportion of subjects with markedly abnormal changes in hematology, clinical chemistry, and urinalysis.

  15. Frequency and Severity of Ovarian Hyperstimulation Syndrome (OHSS) [ Time Frame: From treatment Day 1 to end-of-trial, approximately 10 weeks ]
    Proportion of subjects reporting OHSS classified as mild, moderate, or severe.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women 18-40 years old
  • Body mass index (BMI) between 18 and 38 kg/m2
  • Clinical history or recently diagnosed with primary amenorrhea with hypogonadotropic hypogonadism
  • Hormonal values in a centrally analyzed fasting blood sample: FSH <5 IU/L and mean LH <5 IU/L
  • Desire to become pregnant
  • Discontinued estrogen-progesterone replacement therapy at least 1 month before screening
  • Negative progestin challenge test performed during screening
  • PAP smear within 24 months of the initial visit
  • Normal or stable CT scan or MRI scan of the hypothalamic pituitary region
  • Prolactin and thyroid-stimulating hormone (TSH) within normal clinical laboratory limits
  • Male partner with normal semen analysis, including volume, liquefaction time, sperm count, and motility, according to the local laboratory normal criteria, within the past year
  • Normal transvaginal ultrasound at screening with respect to uterus and adnexa (presence of both ovaries and tubes, without evidence of clinically significant abnormality) and with normal uterine cavity and normal cervix
  • Tube patency on saline tubal perfusion, hysterosalpingography or laparoscopy on file within the past 2 years

Exclusion Criteria:

  • Any medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the drug
  • A history of, or currently diagnosed with clinically important cardiovascular, pulmonary (e.g. serious corticosteroid-dependent asthma), gastrointestinal, hepatic, metabolic, renal, endocrinological (e.g. insulin dependent diabetes mellitus), or neurological (e.g. epilepsy, serious migraine, central nervous system (CNS) lesions (in cases where hypogonadotropic hypogonadism is secondary to a CNS lesion or its treatment) abnormality
  • A history of adrenal or uncontrolled thyroid disorders, or hyperprolactinemia
  • Prior treatment cycle with gonadotropins or GnRH within the last 2 months
  • Known allergy to study drug or its components
  • Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
  • Ovarian enlargement or cyst of unknown etiology
  • Abnormal gynecological bleeding of undetermined origin
  • Previous or current hormone-dependent tumor
  • Known active substance abuse
  • Planning to undergo in vitro fertilization procedure in the course of a study treatment cycle
  • Currently undergoing treatment with gonadotropin hormones (FSH and LH), psychotropic medication, sex hormones, or any other medication known to interfere with normal reproductive function or that can affect GnRH secretion (e.g. neuroleptics, dopamine antagonists, spironolactone, levodopa, phenothiazine, digoxin)
  • Ongoing pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01976728


Locations
Show Show 35 study locations
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Global Clinical Compliance Ferring Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Ferring Pharmaceuticals:
Study Protocol  [PDF] December 6, 2017
Statistical Analysis Plan  [PDF] December 7, 2017

Layout table for additonal information
Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01976728    
Other Study ID Numbers: 000070
First Posted: November 6, 2013    Key Record Dates
Results First Posted: March 3, 2021
Last Update Posted: March 3, 2021
Last Verified: January 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypogonadism
Amenorrhea
Gonadal Disorders
Endocrine System Diseases
Menstruation Disturbances
Pathologic Processes
Prolactin Release-Inhibiting Factors
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs